Clinical Trial: A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Advanced Stage Solid Tumors
Study Type: INTERVENTIONAL
Official Title: A Phase 1 Study of JNJ-79032421, a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors
Brief Summary:
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
Read more